Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy

Cancer

Volumn 117, Issue 9, 2011, Pages 1874-1883

  Xiao, Wei Wei ^a,b   Huang, Shao Min ^a,b   Han, Fei ^a,b   Wu, Shao Xiong ^a,b   Lu, Li Xia ^a,b   Lin, Cheng Guang ^a,b   Deng, Xiao Wu ^a,b   Lu, Tai Xiang ^a,b   Cui, Nian Ji ^a,b   Zhao, Chong ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

late toxicity; local control; nasopharyngeal carcinoma; simultaneous modulated accelerated radiotherapy; survival

Indexed keywords

CISPLATIN;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; BRAIN NECROSIS; BRAIN STEM INJURY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CATARACT; CHEMOTHERAPY INDUCED EMESIS; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DYSPHAGIA; DYSTROPHY; ELECTROLYTE DISTURBANCE; FEMALE; GAIT DISORDER; HEARING IMPAIRMENT; HEARING LOSS; HISTOLOGY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; JAW OSTEONECROSIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NAUSEA; NEUROPATHY; OVERALL SURVIVAL; PARESTHESIA; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SIDE EFFECT; SIMULTANEOUS MODULATED ACCELERATED RADIOTHERAPY; SKIN FIBROSIS; STOMATITIS; TRISMUS; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 79955435781     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25754     Document Type: Article

References (60)

1. Erkal HS, Serin M, Cakmak A., Nasopharyngeal carcinomas: analysis of patient, tumor and treatment characteristics determining outcome. Radiother Oncol. 2001; 61: 247-256. (Pubitemid 33130070)
2. Roychowdhury DF, Tseng A Jr, Fu KK, Weinburg V, Weidner N., New prognostic factors in nasopharyngeal carcinoma. Tumor angiogenesis and C-erbB2 expression. Cancer. 1996; 77: 1419-1426. (Pubitemid 26105375)
3. Liu MT, Hsieh CY, Chang TH, Lin JP, Huang CC, Wang AY., Prognostic factors affecting the outcome of nasopharyngeal carcinoma. Jpn J Clin Oncol. 2003; 33: 501-508.
4. Leung TW, Tung SY, Sze WK, et al. Treatment results of 1070 patients with nasopharyngeal carcinoma: an analysis of survival and failure patterns. Head Neck. 2005; 27: 555-565. (Pubitemid 40961062)
5. Yeh SA, Tang Y, Lui CC, Huang YJ, Huang EY., Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys. 2005; 62: 672-679. (Pubitemid 40779753)
6. Sanguineti G, Geara FB, Garden AS, et al. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. Int J Radiat Oncol Biol Phys. 1997; 37: 985-996. (Pubitemid 27230021)
7. Lee AW, Sze WM, Au JS, et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2005; 61: 1107-1116. (Pubitemid 40340904)
8. Chu AM, Flynn MB, Achino E, Mendoza EF, Scott RM, Jose B., Irradiation of nasopharyngeal carcinoma: correlations with treatment factors and stage. Int J Radiat Oncol Biol Phys. 1984; 10: 2241-2249. (Pubitemid 15197518)
9. Vikram B, Mishra UB, Strong EW, Manolatos S., Patterns of failure in carcinoma of the nasopharynx: I. Failure at the primary site. Int J Radiat Oncol Biol Phys. 1985; 11: 1455-1459. (Pubitemid 15033571)
10. Perez CA, Devineni VR, Marcial-Vega V, Marks JE, Simpson JR, Kucik N., Carcinoma of the nasopharynx: factors affecting prognosis. Int J Radiat Oncol Biol Phys. 1992; 23: 271-280.
11. Ma J, Mai HQ, Hong MH, et al. Is the 1997 AJCC staging system for nasopharyngeal carcinoma prognostically useful for Chinese patient populations ? Int J Radiat Oncol Biol Phys. 2001; 50: 1181-1189. (Pubitemid 32727794)
12. Marks JE, Bedwinek JM, Lee F, Purdy JA, Perez CA., Dose-response analysis for nasopharyngeal carcinoma: an historical perspective. Cancer. 1982; 50: 1042-1050. (Pubitemid 12062879)
13. Le QT, Tate D, Koong A, et al. Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2003; 56: 1046-1054. (Pubitemid 36794036)
14. Teo PM, Leung SF, Tung SY, et al. Dose-response relationship of nasopharyngeal carcinoma above conventional tumoricidal level: a study by the Hong Kong nasopharyngeal carcinoma study group (HKNPCSG). Radiother Oncol. 2006; 79: 27-33. (Pubitemid 44287791)
15. Luo RX, Tang QX, Guo KP, et al. Comparison of continuous and split-course radiotherapy for nasopharyngeal carcinoma-an analysis of 1446 cases with squamous cell carcinoma grade 3. Int J Radiat Oncol Biol Phys. 1994; 30: 1107-1109.
16. Kwong DL, Sham JS, Chau DT, et al. The effect of interruptions and prolonged treatment time in radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1997; 39: 703-710. (Pubitemid 27441440)
17. Lee AW, Chan DK, Fowler JF, et al. Effect of time, dose and fractionation on local control of nasopharyngeal carcinoma. Radiother Oncol. 1995; 36: 24-31.
18. Tate DJ, Adler JR, Chang SD, et al. Stereotactic radiosurgical boost following radiotherapy in primary nasopharyngeal carcinoma: impact on local control. Int J Radiat Oncol Biol Phys. 1999; 45: 915-921. (Pubitemid 29525455)
19. Levendag PC, Lagerwaard FJ, de Pan C, et al. High-dose, high-precision treatment options for boosting cancer of the nasopharynx. Radiother Oncol. 2002; 63: 67-74. (Pubitemid 34626756)
20. Lee AW, Sze WM, Yau TK, et al. Retrospective analysis on treating nasopharyngeal carcinoma with accelerated fractionation (6 fractions per week) in comparison with conventional fractionation (5 fractions per week): Report on 3-year tumor control and normal tissue toxicity. Radiother Oncol. 2001; 58: 121-130. (Pubitemid 32146513)
21. Wolden SL, Zelefsky MJ, Hunt MA, et al. Failure of a 3D conformal boost to improve radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2001; 49: 1229-1234. (Pubitemid 32294301)
22. Jen YM, Lin YS, Su WF, et al. Dose escalation using twice-daily radiotherapy for nasopharyngeal carcinoma: does heavier dosing result in a happier ending ? Int J Radiat Oncol Biol Phys. 2002; 54: 14-22.
23. Teo PM, Leung SF, Chan AT, et al. Final report of a randomized trial on altered-fractionated radiotherapy in nasopharyngeal carcinoma prematurely terminated by significant increase in neurologic complications. Int J Radiat Oncol Biol Phys. 2000; 48: 1311-1322.
24. Lu H, Yao M., The current status of intensity-modulated radiation therapy in the treatment of nasopharyngeal carcinoma. Cancer Treat Rev. 2008; 34: 27-36. (Pubitemid 351187501)
25. Xia P, Fu KK, Wong GW, Akazawa C, Verhey LJ., Comparison of treatment plans involving intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2000; 48: 329-337.
26. Cheng JC, Chao KS, Low D., Comparison of intensity modulated radiation therapy (IMRT) treatment techniques for nasopharyngeal carcinoma. Int J Cancer. 2001; 96: 126-131. (Pubitemid 32291433)
27. Hunt MA, Zelefsky MJ, Wolden S, et al. Treatment planning and delivery of intensity-modulated radiation therapy for primary nasopharynx cancer. Int J Radiat Oncol Biol Phys. 2001; 49: 623-632. (Pubitemid 32112190)
28. Kam MK, Chau RM, Suen J, Choi PH, Teo PM., Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation. Int J Radiat Oncol Biol Phys. 2003; 56: 145-157. (Pubitemid 36403686)
29. Butler EB, Teh BS, Grant WH III, et al. Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys. 1999; 45: 21-32. (Pubitemid 29380070)
30. Teh BS, Woo SY, Butler EB., Intensity modulated radiation therapy (IMRT): a new promising technology in radiation oncology. Oncologist. 1999; 4: 433-442. (Pubitemid 30013177)
31. Lee SW, Back GM, Yi BY, et al. Preliminary results of a phase I/II study of simultaneous modulated accelerated radiotherapy for nondisseminated nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006; 65: 152-160.
32. Kim K, Wu HG, Kim HJ, et al. Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Head Neck. 2009; 31: 1121-1128.
33. Chen SW, Yang SN, Liang JA, Shiau AC, Lin FJ., Comparative dosimetric study of 2 strategies of intensity-modulated radiotherapy in nasopharyngeal cancer. Med Dosim. 2005; 30: 219-227.
34. Koom WS, Kim TH, Shin KH, et al. SMART (simultaneous modulated accelerated radiotherapy) for locally advanced nasopharyngeal carcinomas. Head Neck. 2008; 30: 159-169.
35. Kwong DL, Sham JS, Leung LH, et al. Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006; 64: 374-381. (Pubitemid 43083421)
36. Wolden SL, Chen WC, Pfister DG, Kraus DH, Berry SL, Zelefsky MJ., Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys. 2006; 64: 57-62. (Pubitemid 41831209)
37. Lin S, Pan J, Han L, Zhang X, Liao X, Lu JJ., Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective series. Int J Radiat Oncol Biol Phys. 2009; 75: 1071-1078.
38. Fleming ID, Cooper JS, Henson DE, et al. AJCC Cancer Staging Manual. 5th ed. Philadelphia, PA: Lippincott-Raven; 1997.
39. International Commission on Radiation Units and Measurements. Report 50: Prescribing, recording, and reporting photon beam therapy. Bethesda, MD: ICRU; 1993.
40. International Commission on Radiation Units and Measurements. Report 62: Prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50). Bethesda, MD: ICRU; 1999.
41. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase 3 randomized Intergroup study 0099. J Clin Oncol. 1998; 16: 1310-1317. (Pubitemid 28175745)
42. Orton CG., Recent developments in time-time modeling. Australas Phys Eng Sci Med. 1991; 14: 57-64.
43. Barendsen GW., Dose rate and isoeffect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys. 1982; 8: 1981-1997. (Pubitemid 13167385)
44. Dale EG., The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol. 1985; 58: 515-528.
45. Fowler JF., Brief summary of radiobiological principles in fractionated radiotherapy. Semin Radiat Oncol. 1992; 2: 16-21.
46. Kaplan EL, Meier P., Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 457-481.
47. Cox JD, Stetz J, Pajak TF., Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 13: 1341-1346.
48. Fleming ID, Cooper JS, Henson DE., American Joint Committee on Cancer: AJCC Cancer Staging Manual. New York, NY: Springer-Verlag; 2002.
49. Sobin LH, Wittekind CH., International Union Against Cancer (UICC): TNM Classification of Malignant Tumors. New York, NY: Wiley-Liss; 2002.
50. Lee AW, Tung SY, Chua DT, et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy versus radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2010; 102: 1188-1198.
51. Palazzi M, Guzzo M, Tomatis S, et al. Improved outcome of nasopharyngeal carcinoma treated with conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2004; 60: 1451-1458. (Pubitemid 39601862)
52. Wu S, Xie C, Jin X, et al. Simultaneous modulated accelerated radiation therapy in the treatment of nasopharyngeal carcinoma: a local center';s experience. Int J Radiat Oncol Biol Phys. 2006; 66 (4 suppl): S44-S46.
53. Lee N, Harris J, Garden AS, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: Radiation Therapy Oncology Group phase II trial 0225. J Clin Oncol. 2009; 27: 3684-3690.
54. Tham IW, Hee SW, Yeo RM, et al. Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy-the National Cancer Centre Singapore experience. Int J Radiat Oncol Biol Phys. 2009; 75: 1481-1486.
55. Kam MK, TeoPML, Chau RMC, et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2004; 60: 1440-1450. (Pubitemid 39601861)
56. Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002; 53: 12-22. (Pubitemid 34465802)
57. Langendijk JA, Leemans CR, Buter J, Berkhof J, Slotman BJ., The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol. 2004; 22: 4604-4612. (Pubitemid 41185128)
58. Lee AW, Tung SY, Chan AT, et al. Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006; 66: 142-151. (Pubitemid 44175659)
59. Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, et al. Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomized, noninferiority, open trial. Eur J Cancer. 2007; 43: 1399-1406. (Pubitemid 46874069)
60. Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009; 27: 242-249.